(Q46313788)

21 December 2017

title

Mycophenolate mofetil versus azathioprine in the maintenance therapy of lupus nephritis (English)

1 reference

21 December 2017

1 reference

Gulizar Manga Sahin

1

1 reference

21 December 2017

Sevgi Sahin

2

1 reference

21 December 2017

Safak Kiziltas

3

1 reference

21 December 2017

Seval Masatlioglu

4

1 reference

21 December 2017

Fusun Oguz

5

1 reference

21 December 2017

Hulya Ergin

6

1 reference

21 December 2017

publication date

1 January 2008

1 reference

21 December 2017

published in

Renal Failure

1 reference

21 December 2017

volume

30

1 reference

21 December 2017

issue

9

1 reference

21 December 2017

page(s)

865-869

1 reference

21 December 2017

Improved clinical outcome of lupus nephritis during the past decade: importance of early diagnosis and treatment

cites work

1 reference

https://api.crossref.org/works/10.1080%2F08860220802353843

Trends in the incidence and mortality of systemic lupus erythematosus, 1950-1992.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08860220802353843

Mycophenolate mofetil and its mechanisms of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08860220802353843

Lymphocyte-Selective Cytostatic and Immunosuppressive Effects of Mycophenolic Acid in Vitro: Role of Deoxyguanosine Nucleotide Depletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08860220802353843

Mycophenolate mofetil inhibits rat and human mesangial cell proliferation by guanosine depletion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08860220802353843

Effect of mycophenolate mofetil on severity of nephritis and nitric oxide production in lupus-prone MRL/lpr mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08860220802353843

Relapses of lupus nephritis: incidence, risk factors, serology and impact on outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08860220802353843

"Nephritic flares" are predictors of bad long-term renal outcome in lupus nephritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08860220802353843

Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08860220802353843

Effects of cyclophosphamide on the development of malignancy and on long‐term survival of patients with rheumatoid arthritis a 20‐year followup study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08860220802353843

Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08860220802353843

Sequential therapies for proliferative lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08860220802353843

10.1080/08860220802353843

21 January 2018

Identifiers

DOI

1 reference

21 December 2017

1 reference

21 December 2017